Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2026 Feb;84(2):275-283.
doi: 10.1016/j.jhep.2025.09.024. Epub 2025 Oct 3.

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

Yu Jun Wong  1 Laurent Lam  2 Pierre-Antoine Soret  3 Sara Lemoinne  2 Bettina Hansen  4 Gideon Hirschfield  5 Aliya Gulamhusein  5 Ellina Lytvyak  6 Albert Pares  7 Ignasi Olivas  7 Maria-Carlota Londono  7 Sergio Rogriguez-Tajes  7 John E Eaton  8 Karim T Osman  8 Christoph Schramm  9 Marcial Sebode  9 Ansgar W Lohse  9 George Dalekos  10 Nikolaos Gatselis  10 Frederik Nevens  11 Nora Cazzagon  12 Alessandra Zago  13 Francesco Paolo Russo  12 Annarosa Floreani  12 Nadir Abbas  14 Palak Trivedi  15 Douglas Thorburn  16 Francesca Saffioti  17 Laszlo Barkai  16 Davide Roccarina  16 Vicenza Calvaruso  18 Anna Fichera  18 Adèle Delamarre  19 Natalia Sobenko  20 Alejandra Maria Villamil  20 Esli Medina-Morales  21 Alan Bonder  21 Vilas Patwardhan  21 Cristina Rigamonti  22 Marco Carbone  23 Pietro Invernizzi  24 Laura Cristoferi  25 Adriaan van der Meer  26 Rozanne de Veer  26 Ehud Zigmond  27 Eyal Yehezkel  27 Andreas E Kremer  28 Ansgar Deibel  28 Tony Bruns  29 Karsten Große  29 Aaron Wetten  30 Jessica Katharine Dyson  30 David Jones  30 Cynthia Levy  31 Atsushi Tanaka  32 Jérôme Dumortier  33 Georges-Philippe Pageaux  34 Victor de Lédinghen  19 Fabrice Carrat  2 Olivier Chazouillères  2 Christophe Corpechot  35 Aldo J Montano-Loza  36 Global & ERN Rare-Liver PBC Study Groups
Affiliations
Free article
Observational Study

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

Yu Jun Wong et al. J Hepatol. 2026 Feb.
Free article

Abstract

Background & aims: Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the frequency and clinical relevance of discordant biochemical and LSM changes remain unclear. We aim to determine the performance of the most recent or current LSM (LSMc) in predicting first hepatic decompensation (HD) in the setting of discordant biochemical and LSM responses.

Methods: In this international, multicenter study, we included patients with at least two reliable LSM performed at least 6 months apart. Patients with prior HD, liver transplantation or hepatocellular carcinoma were excluded. Biochemical response was based on the Paris-II criteria. LSM response was defined as stable or any reduction in LSM. The primary outcome was the occurrence of the first HD. Secondary outcomes were liver transplantation and liver-related death. The influence of LSM on HD was estimated using Cox regression analysis.

Results: A total of 1,793 patients with PBC were analyzed. Over a median follow-up of 22 (IQR 12-39) months, 3.3% developed HD. Up to 55% of patients with PBC exhibited discordance between LSM and biochemical response. Among patients with LSM response, achieving Paris-II criteria was associated with a lower risk of HD (hazard ratio [HR] 0.25, 95% CI 0.06-0.97, p <0.044). Among patients with biochemical response, LSM response did not influence the risk of developing HD (HR 0.64, 95% CI 0.21-1.96, p = 0.429). The LSMc >10 kPa strongly predicted HD (HR 14.5, 95% CI 6.9-30.6, p <0.001), irrespective of biochemical response and prior LSM trajectories.

Conclusions: Discordance between LSM and biochemical response is frequent. Most recent or current LSM is the strongest predictor of first liver-related events in patients with PBC, irrespective of prior biochemical response or LSM trajectory.

Impact and implications: Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis. However, the clinical relevance and how discordant biochemical and LSM changes should be best interpreted remain unclear. In this large international multicenter study, we demonstrated that once the current LSM is known, prior LSM trajectories and biochemical changes did not improve the prediction of liver-related events in patients with primary biliary cholangitis. Our finding addresses a common clinical dilemma in risk-stratifying PBC patients with discordant biochemical and LSM responses. Importantly, the use of the latest LSM value for risk prediction significantly simplifies the use of LSM in clinical decision-making for PBC patients with multiple LSM readings.

Keywords: Liver stiffness; clinically significant portal hypertension; decompensation; non-invasive; portal hypertension; prediction; vibration-controlled elastography.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest These authors disclose the following: A.J. Montano-Loza has served on advisory boards for Intercept Pharmaceuticals. B.E. Hansen reports grants from Intercept Pharmaceuticals and Zambon Nederland B.V. and consulting work for Intercept Pharmaceuticals and Novartis. A.E. Kremer reports consulting work for Advanz, CymaBay, Dr. Falk Pharma, Gilead, GSK, Intercept Pharmaceuticals, Ipsen, and Mirum and grants from Gilead and Intercept Pharmaceuticals. A. Parés consults for Intercept and Novartis. A. Floreani reports consulting activities for Intercept Pharmaceuticals. P. Trivedi has received grant support from the Wellcome Trust, the Medical Research Foundation, GlaxoSmithKline, Guts UK, PSC Support, LifeArc, NIHR, Intercept Pharma, Dr Falk Pharma, Gilead Sciences, and Bristol Myers Squibb. He has also received speaker fees from Albireo/IPSEN, Advanz/Intercept and Dr. Falk, and advisory board/consultancy fees from ChemoMab, Cymabay, Intercept, Dr. Falk Pharma, Albireo/Ipsen, Pliant Pharma and GlaxoSmithKline. He received grants from Merck. C. Corpechot reports grants from Intercept Pharmaceuticals, and consulting work for Echosens, Cymabay, Gilead, Ipsen, Calliditas, and Intercept Pharmaceuticals. T. Bruns has served on advisory boards for AdvanzPharma/Intercept Pharmaceuticals and Gilead, and has received speaker fees from Dr Falk Pharma. J. Dyson has received speaker fees from Intercept Pharmaceuticals and Dr. Falk Pharma, GSL, Ipsen and Intercept and received consultancy fees from Umecrine, and acted as a scientific expert for NICE. G. Dalekos reports consulting activities and speaker fees for Genesis Pharma, Gilead and Ipsen. C. Rigamonti has received speaker fees from Advanz Pharma. The remaining authors disclose no conflicts. Please refer to the accompanying ICMJE disclosure forms for further details.

Publication types

LinkOut - more resources